| Symbol | PTIX |
|---|
| Name | PROTAGENIC THERAPEUTICS, INC. |
|---|
| Sector | HEALTH CARE |
|---|
| Region | North America |
|---|
| Industry | - |
|---|
| Address | 10010 United States NY 149 Fifth Avenue Suite 500 |
|---|
| Telephone | +1 (212) 994-8200 |
|---|
| Fax | — |
|---|
| Email | — |
|---|
| Website | https://protagenic.com/ |
|---|
| Incorporation | US |
|---|
| Incorporated On | 1994 |
|---|
| Employees | — |
|---|
| Fiscal Year | 3/31 |
|---|
| Public Since | — |
|---|
| Exchanges | OTC;NASDAQ;Pink Limited |
|---|
| Auditor | MaloneBailey, LLP;GreenGrowth CPAs; |
|---|
| Audit Status | AUDITED |
|---|
| Reporting Status | U.S. Reporting: SEC Reporting |
|---|
| CIK | 0001022899 |
|---|
| Description | Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The companys lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Additional info from NASDAQ:
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The companys lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Additional info from OTC:
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The companys lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.
Additional info from Pink Limited:
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The companys lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. |
|---|
No clinical trials found for this company.
No clinical products found for this company.